UCB’s core antibody discovery platform combines high-throughput B cell culture screening, and the identification and isolation of single, antigen specific IgG-secreting B cells through a proprietary technique called the ‘fluorescent foci method’. Using state of the art automation to facilitate screening , extremely efficient interrogation of the natural antibody repertoire is made possible; in fact, more than one billion immune B cells can now be screened to identify therapeutic antibody candidates.

This poster will describe our core antibody discovery process and focus on the integration of our bespoke automation system to provide efficiency savings and improvements in antibody quality. It will also highlight how we are developing our screening capabilities to allow for more complicated multiplex assays, allowing us to identify multiple binding profiles of antibodies in a single experiment.